Candel Therapeutics (CADL) Operating Expenses (2020 - 2023)
Historic Operating Expenses for Candel Therapeutics (CADL) over the last 4 years, with Q4 2023 value amounting to $10.3 million.
- Candel Therapeutics' Operating Expenses rose 2688.15% to $10.3 million in Q4 2023 from the same period last year, while for Dec 2023 it was $38.4 million, marking a year-over-year increase of 1017.65%. This contributed to the annual value of $33.4 million for FY2024, which is 1307.6% down from last year.
- According to the latest figures from Q4 2023, Candel Therapeutics' Operating Expenses is $10.3 million, which was up 2688.15% from $8.9 million recorded in Q3 2023.
- Over the past 5 years, Candel Therapeutics' Operating Expenses peaked at $10.3 million during Q4 2023, and registered a low of $2.6 million during Q2 2020.
- Its 4-year average for Operating Expenses is $7.4 million, with a median of $8.1 million in 2022.
- In the last 5 years, Candel Therapeutics' Operating Expenses soared by 18992.81% in 2021 and then tumbled by 57.23% in 2023.
- Over the past 4 years, Candel Therapeutics' Operating Expenses (Quarter) stood at $6.2 million in 2020, then rose by 26.23% to $7.8 million in 2021, then increased by 4.65% to $8.1 million in 2022, then rose by 26.88% to $10.3 million in 2023.
- Its Operating Expenses was $10.3 million in Q4 2023, compared to $8.9 million in Q3 2023 and $9.6 million in Q2 2023.